Opthea reports Fiscal Year 2021 Results and Highlights
Filed with ASX · · 2 pages · English
Earlier from Opthea
- Optheas OPT-302 Granted Fast-Track for wet AMD
- Opthea Receives FDA Waiver for Pediatric Study Plan
- Opthea Treats First Patient in Phase 3 Trials of OPT-302
- Opthea Finalizes Ph 3 Study Designs and Startup Activities
- Opthea Receives A$8.5m R&D Tax Incentive
Later from Opthea
- Optheas Phase 3 open for patient recruitment in Europe
- Opthea Corporate Presentation - October 2021
- Opthea opens patient enrollment in the Asia-Pacifi Region
- Opthea Granted Chinese Patent Covering OPT-302
- Opthea Receives A$6.6m R&D Tax Incentive
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea